Read More Pharma Industry News Incyte’s dual-target antibody and KRAS G12D drug show early promise in hard-to-treat colorectal and pancreatic cancers Find out how Incyte’s Phase 1 cancer data could transform treatment for colorectal and pancreatic patients—read what’s driving investor optimism today! bySoujanya RaviOctober 19, 2025